Intellia's Hereditary Angioedema Candidate Shows Reduction In Associated Biomarkers, Attack Rates

Intellia Therapeutics Inc NTLA announced updated data from an ongoing Phase 1/2 study of NTLA-2002 for hereditary angioedema (HAE).
Single doses of 25 mg (n=3), 50 mg (n=4), and 75 mg (n=3) of NTLA-2002 were administered via intravenous infusion.
Administration of NTLA-2002 led to deep, dose-dependent reductions in plasma kallikrein.
For the 25 mg and 75 mg cohorts, these deep reductions in plasma kallikrein were sustained through the observation period, which ranged from week 16 to week 32.
Related: Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies.
All patients treated in the 25 mg and 75 mg cohorts have an ongoing attack-free interval through the latest follow-up.
The first three patients treated have an ongoing attack-free interval of 5.5 – 10.6 months after a single dose of NTLA-2002.
At all three dose levels, NTLA-2002 was generally well-tolerated, and the majority of adverse events were mild in severity.
Intellia expects to select up to two doses to further evaluate NTLA-2002 in the Phase 2 study, which is expected to begin in 1H of 2023.
Price Action: NTLA shares closed higher by 4.17% at $54.95 on Friday.